Quintrio
Home

MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

FitLife Brands, Inc. Common Stock

FTLF

FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Dr. Tobias, MusclePharm, Irwin Naturals, Applied Nutrition, Isatori, and Nature's Secret brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.

Last trade $6.75
Day change -$0.08 (-1.17%)
Day range $6.55 – $6.83
Volume 22,232
Market cap $64M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$64.14M
Price / earnings
10.29×
Price / book
1.35×
Price / sales
0.63×
EV / sales
1×
EV / EBITDA
7.96×

Profitability

Earnings per share
$0.66
Return on assets
6.07%
Return on equity
13.15%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.8×
Current ratio
1.46×
Quick ratio
0.45×
Cash ratio
0.05×

Cash flow

Price / cash flow
6.39×
Price / free cash flow
—
Free cash flow
-$32.48M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for FTLF, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$26.55M$25.33M$25.91M$23.49M$16.13M$15.94M$15.01M$15.98M
Cost of revenue$16.74M$15.81M$16.97M$14.75M$9.22M$9.06M$8.8M$8.98M
Gross profit$9.81M$9.52M$8.94M$8.74M$6.9M$6.87M$6.21M$7M
Selling, general and administrative$6.2M$6.21M$6.19M$5.46M$3.68M$3.57M$3.27M$3.74M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$6.46M$6.46M$6.67M$6.42M$4.39M$3.92M$3.33M$3.82M
Operating income$3.36M$3.06M$2.27M$2.32M$2.52M$2.96M$2.88M$3.18M
Interest expense-$679K-$735K-$814K-$580K-$175K-$244K-$282K-$326K
Income before taxes$2.68M$2.35M$1.38M$1.75M$2.38M$2.72M$2.65M$2.9M
Income taxes$734K$627K-$258K$829K$631K$701K$581K$770K
Net income$1.95M$1.72M$1.64M$921K$1.75M$2.02M$2.07M$2.13M
Net income attributable to common shareholders$1.95M$1.72M$1.64M$921K$1.75M$2.02M$2.07M$2.13M
EBITDA$3.61M$3.31M$2.5M$3.27M$3.23M$3.29M$2.94M$3.26M
Basic earnings per share$0.21$0.18$0.17$0.10$0.19$0.22$0.23$0.23
Diluted earnings per share$0.20$0.17$0.16$0.09$0.18$0.20$0.21$0.21

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

FitLife Brands Inc. (FTLF) Q3 Earnings and Revenues Lag Estimates

FitLife Brands reported quarterly earnings of $0.19 per share, missing the consensus estimate of $0.25 and representing a -24% earnings surprise. Revenue also fell short of expectations at $25.62 million versus the estimate. The stock has significantly underperformed the market, declining 47.9% year-to-date compared to the S&P 500's 10.5% gain. With a Zacks Rank #3 (Hold) rating and the Medical-Products industry in the bottom 43% of performance, the outlook remains uncertain pending management commentary.

Zacks Investment Research

Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates

Nektar Therapeutics reported a quarterly loss of $1.63 per share, beating the consensus estimate of $2.16 loss by 24.54%, but missed revenue expectations with $9.39 million versus the estimated $10.23 million. The stock has underperformed the S&P 500 by 20.4% year-to-date. Despite the revenue miss, Nektar holds a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.

Zacks Investment Research

Phibro Animal Health (PAHC) Q1 Earnings Match Estimates

Phibro Animal Health (PAHC) reported Q3 2026 earnings of $0.79 per share, matching consensus estimates, with revenues of $386.8 million exceeding expectations by 2.05%. The company has outperformed estimates three times over the last four quarters. Despite favorable estimate revisions earning a Zacks Rank #2 (Buy) rating, PAHC has underperformed the S&P 500 year-to-date, gaining only 0.8% versus the market's 10.6% gain. The Medical-Products industry ranks in the bottom 37% of Zacks industries.

Zacks Investment Research

Best Value Stocks to Buy for October 7th

Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong value characteristics: FitLife Brands (FTLF), a nutritional supplements company with a P/E of 10.41 and Value Score A; Imperial Oil (IMO), an oil and gas explorer with a P/E of 11.04 and Value Score B; and Permian Resources (PR), an oil and gas company with a P/E of 9.79 and Value Score B. All three have seen earnings estimate increases over the last 60 days.

GlobeNewswire Inc.

FitLife Brands Announces Second Quarter Earnings Call

FitLife Brands, Inc. (Nasdaq: FTLF), a nutritional supplements and wellness products provider, announced it will report its second quarter fiscal 2026 financial performance on August 13, 2026, followed by an investor conference call at 4:30 pm ET. The company markets over 500 products online and through retail locations from its Omaha, Nebraska headquarters.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 7, 20252-for-1forward split
Dec 8, 20214-for-1forward split
Apr 16, 2019800-for-1forward split
Apr 16, 20191-for-8,000reverse split